Please use this identifier to cite or link to this item:
Title: Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the new world
Authors: Salay, Gerson [UNIFESP]
Dorta, M. L. [UNIFESP]
Santos, N. M. [UNIFESP]
Mortara, Renato Arruda [UNIFESP]
Brodskyn, C.
Oliveira, C. I.
Barbieri, C. L. [UNIFESP]
Rodrigues, Mauricio M. [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Fdn Oswaldo Crus
Univ Fed Gouania
Universidade Federal da Bahia (UFBA)
Issue Date: 1-Sep-2007
Publisher: Amer Soc Microbiology
Citation: Clinical and Vaccine Immunology. Washington: Amer Soc Microbiology, v. 14, n. 9, p. 1173-1181, 2007.
Abstract: We evaluated whether four recombinant antigens previously used for vaccination against experimental infection with Leishmania (Leishmania) major could also induce protective immunity against a challenge with Leishmania (Viannia) braziliensis, the species responsible for 90% of the 28,712 annual cases of cutaneous and mucocutaneous leishmaniasis recorded in Brazil during the year of 2004. Initially, we isolated the homolog genes encoding four L. (V.) braziliensis antigens: (i) homologue of receptor for activated C kinase, (ii) thiol-specific antioxidant, (iii) Leishmania elongation and initiation factor, and (iv) L. (L.) major stress-inducible protein 1. At the deduced amino acid level, all four open reading frames had a high degree of identity with the previously described genes of L. (L.) major being expressed on promastigotes and amastigotes of L. (V.) braziliensis. These genes were inserted into the vector pcDNA3 or expressed as bacterial recombinant proteins. After immunization with recombinant plasmids or proteins, BALB/c mice generated specific antibody or cell-mediated immune responses (gamma interferon production). After an intradermal challenge with L. (V.) braziliensis infective promastigotes, no significant reduction on the lesions was detected. We conclude that the protective immunity afforded by these four vaccine candidates against experimental cutaneous leishmaniasis caused by L. (L.) major could not be reproduced against a challenge with L. (V.) braziliensis. Although negative, we consider our results important since they suggest that studies aimed at the development of an effective vaccine against L. (V.) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World, should be redirected toward distinct antigens or different vaccination strategies.
ISSN: 1556-6811
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
File Description SizeFormat 
WOS000249488400015.pdf598.95 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.